Mereo BioPharma Group plc 8-K

What Happened
Mereo BioPharma Group plc (MREO) announced on Feb. 17, 2026 that Nasdaq’s Listings Qualifications Department sent a Notification Letter saying the company’s American Depositary Shares (ADSs) failed to maintain the $1.00 minimum bid price required by Nasdaq Listing Rule 5550(a)(2). The notice does not cause immediate delisting and the ADSs will continue to trade under the symbol "MREO."

Key Details

• Nasdaq issued the notice on February 17, 2026 under Listing Rule 5550(a)(2).
• Mereo has a 180-calendar-day compliance period (until August 17, 2026) to regain compliance.
• To regain compliance, the ADS closing bid must be at least $1.00 for a minimum of 10 consecutive business days (unless Nasdaq extends this period).
• If not cured by Aug. 17, 2026, Mereo may be eligible for an additional 180-day grace period only if it meets Nasdaq’s market value of publicly held shares and other initial listing standards (except the bid-price rule) and provides written notice to cure.
• If the company remains noncompliant and is not eligible for a second period, Nasdaq would notify the company that the ADSs are subject to delisting; Mereo could appeal to a Nasdaq hearing panel.
• The company stated its business operations are not affected by the notice. The 8‑K was signed by CFO Christine Fox.

Why It Matters
This is a regulatory compliance issue—not an immediate trading halt or delisting—but it signals a risk to listing status that can affect liquidity, investor perception and share price if not cured. Investors should note the Aug. 17, 2026 compliance deadline and monitor the ADS closing price and company updates. The company disclosed forward‑looking statements and warned there is no assurance it will regain compliance.